CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) targeting programmed death 1/ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have transformed the therapeutic landscape of many cancers and have shown significant efficacy in multiple tumor types.[5,6] The toxic effects related to ICIs may affect any organ and arise from the activation of autoreactive T cells that destroy host tissues.